FDA approves nasal spray for treatment-resistant depression
CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral ...
FDA approves first-of-its-kind nasal spray for severe depression
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...
Oncology Nurse Advisor13h
Mesenchymal Stromal Cell Therapy Ryoncil Gets FDA Approval
The Food and Drug Administration (FDA) has approved Ryoncil ® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft vs host disease (SR-aGvHD) in pediatric patients 2 months of age ...
Rigel Pharmaceuticals enrolls first patient in Phase 1 study of fostamatinib
Rigel Pharmaceuticals (RIGL) announced the first patient has been enrolled in a Phase 1 study evaluating the safety and tolerability of ...